Ipratropiumbromid Stulln (Ipratropium Bromide)

Ipratropium bromide works by competitively blocking muscarinic (M3) acetylcholine receptors on airway smooth muscle. This inhibition prevents acetylcholine‑mediated bronchoconstriction, leading to relaxation of the bronchial muscles and increased airflow through the lungs.

The specific dose and frequency are determined by the prescribing healthcare professional based on the patient’s condition, severity, and response to therapy. Typical regimens involve inhalation via a nebulizer or metered‑dose inhaler, but the exact dosing must be individualized by the prescriber.

Safety data for ipratropium bromide in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with a healthcare provider is essential before use in these populations.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. The sales team will verify trade or institutional credentials and then provide pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Ipratropium bromide is an anticholinergic bronchodilator, whereas beta‑2 agonists such as albuterol act on adrenergic receptors to relax airway smooth muscle. Anticholinergics tend to have a slower onset but provide sustained bronchodilation and are often used as add‑on therapy. Long‑acting agents like tiotropium share a similar mechanism but have a longer duration of action.

Store the product at room temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light. Do not expose the inhalation device to extreme temperatures or humidity, and ensure the container is tightly closed when not in use.

The medication is delivered by inhalation, either through a nebulizer solution or a metered‑dose inhaler, as directed by the prescriber. The patient inhales the dose directly into the lungs, allowing the drug to act locally on airway smooth muscle.

Serious risks include urinary retention, especially in patients with prostate enlargement; exacerbation of narrow‑angle glaucoma leading to increased intra‑ocular pressure; severe allergic reactions such as anaphylaxis; and paradoxical bronchospasm, which requires immediate medical attention.

Patients with known hypersensitivity to ipratropium bromide or any formulation components should avoid the product. Individuals with narrow‑angle glaucoma, significant urinary retention, or severe prostate hypertrophy should not use it without close medical supervision. Contraindications must be evaluated by a qualified healthcare professional.